ASCENTAGE-B News

ASCENTAGE-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Apr 15 10:27 ET

ASCENTAGE-B: Notification Letter and Request Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Apr 15 06:33 ET

ASCENTAGE-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 10, 2024

Apr 15 06:27 ET

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - ACQUISITION OF SHARES BY THE CHAIRMAN AND EXECUTIVE DIRECTOR

Apr 8 10:52 ET

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS RESULTS FROM THREE STUDIES AT 2024 AMERICAN ASSOCIATION OF CANCER RESEARCH ANNUAL MEETING

Apr 7 19:50 ET

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - ACQUISITION OF SHARES BY DIRECTORS

Apr 3 10:45 ET

ASCENTAGE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 3 09:53 ET

ASCENTAGE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 6 09:04 ET

ASCENTAGE-B: Voluntary Announcement - Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Mar 5 18:38 ET

ASCENTAGE-B: Voluntary Announcement - Ascentage Pharma Received Clearance from U.S. FDA to Initiate Global Registrational Phase 3 Clinical Trial for Olverembatinib in Previously Treated Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Feb 13 18:47 ET

ASCENTAGE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Feb 6 09:24 ET

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME

Feb 2 08:39 ET

ASCENTAGE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

Jan 5 09:51 ET

ASCENTAGE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023

Dec 5, 2023 09:37 ET

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - OLVEREMBATINIB APPROVED BY NMPA FOR TREATMENT OF CML-CP PATIENTS WHO ARE RESISTANT AND/OR INTOLERANT TO 1st AND 2nd GENERATION TKI TREATMENT

Nov 17, 2023 07:12 ET

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME

Nov 16, 2023 08:18 ET

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME

Nov 14, 2023 07:37 ET

ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME

Nov 13, 2023 08:23 ET

ASCENTAGE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023

Nov 6, 2023 09:52 ET

ASCENTAGE-B: Voluntary Announcement - Ascentage Pharma to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology (ASH) Annual Meeting, two of which have been Selected for Oral Reports

Nov 2, 2023 19:58 ET